-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head-To-Head Analysis: PAVmed (NASDAQ:PAVM) and EnVVeno Medical (NASDAQ:NVNO)
Head-To-Head Analysis: PAVmed (NASDAQ:PAVM) and EnVVeno Medical (NASDAQ:NVNO)
PAVmed (NASDAQ:PAVM – Get Rating) and enVVeno Medical (NASDAQ:NVNO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.
Profitability
This table compares PAVmed and enVVeno Medical's net margins, return on equity and return on assets.
Get PAVmed alerts:Net Margins | Return on Equity | Return on Assets | |
PAVmed | N/A | -112.81% | -70.55% |
enVVeno Medical | N/A | -56.38% | -53.02% |
Earnings & Valuation
This table compares PAVmed and enVVeno Medical's revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
PAVmed | $500,000.00 | 83.52 | -$50.35 million | ($0.98) | -0.47 |
enVVeno Medical | N/A | N/A | -$16.53 million | ($2.58) | -1.88 |
Risk & Volatility
PAVmed has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for PAVmed and enVVeno Medical, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
PAVmed | 0 | 0 | 2 | 0 | 3.00 |
enVVeno Medical | 0 | 0 | 0 | 0 | N/A |
PAVmed presently has a consensus target price of $4.25, indicating a potential upside of 826.13%. Given PAVmed's higher possible upside, research analysts clearly believe PAVmed is more favorable than enVVeno Medical.
Institutional & Insider Ownership
14.0% of PAVmed shares are held by institutional investors. Comparatively, 23.1% of enVVeno Medical shares are held by institutional investors. 14.6% of PAVmed shares are held by company insiders. Comparatively, 16.3% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
enVVeno Medical beats PAVmed on 6 of the 11 factors compared between the two stocks.
About PAVmed
(Get Rating)
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.
About enVVeno Medical
(Get Rating)
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
PAVmed (NASDAQ:PAVM – Get Rating) and enVVeno Medical (NASDAQ:NVNO – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.
PAVMED(納斯達克:PAVM-GET Rating)和enVVeno Medical(納斯達克:NVNO-GET Rating)都是小盤醫療公司,但哪隻股票更具優勢?我們將根據兩家公司的盈利實力、分析師建議、估值、股息、風險、盈利能力和機構持股情況對兩家公司進行比較。
Profitability
盈利能力
This table compares PAVmed and enVVeno Medical's net margins, return on equity and return on assets.
此表比較了PAVmed和enVVeno Medical的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
PAVmed | N/A | -112.81% | -70.55% |
enVVeno Medical | N/A | -56.38% | -53.02% |
淨利潤率 | 股本回報率 | 資產回報率 | |
PAVmed | 不適用 | -112.81% | -70.55% |
EnVVeno醫療 | 不適用 | -56.38% | -53.02% |
Earnings & Valuation
收益與估值
This table compares PAVmed and enVVeno Medical's revenue, earnings per share and valuation.
此表比較了PAVmed和enVVeno Medical的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
PAVmed | $500,000.00 | 83.52 | -$50.35 million | ($0.98) | -0.47 |
enVVeno Medical | N/A | N/A | -$16.53 million | ($2.58) | -1.88 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
PAVmed | $500,000.00 | 83.52 | -5,035萬元 | ($0.98) | -0.47 |
EnVVeno醫療 | 不適用 | 不適用 | -1,653萬美元 | ($2.58) | -1.88 |
Risk & Volatility
風險與波動性
PAVmed has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.
PAVmed的貝塔係數為0.79,表明其股價的波動性比標準普爾500指數低21%。相比之下,enVVeno Medical的貝塔係數為1.27,這表明其股價的波動性比標準普爾500指數高27%。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings for PAVmed and enVVeno Medical, as provided by MarketBeat.
這是MarketBeat提供的PAVmed和enVVeno Medical最近的評級細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
PAVmed | 0 | 0 | 2 | 0 | 3.00 |
enVVeno Medical | 0 | 0 | 0 | 0 | N/A |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
PAVmed | 0 | 0 | 2 | 0 | 3.00 |
EnVVeno醫療 | 0 | 0 | 0 | 0 | 不適用 |
PAVmed presently has a consensus target price of $4.25, indicating a potential upside of 826.13%. Given PAVmed's higher possible upside, research analysts clearly believe PAVmed is more favorable than enVVeno Medical.
PAVmed目前的共識目標價為4.25美元,表明潛在上行826.13%。考慮到PAVmed更有可能的上行空間,研究分析師顯然認為,PAVmed比enVVeno Medical更有利。
Institutional & Insider Ownership
機構與內部人持股
14.0% of PAVmed shares are held by institutional investors. Comparatively, 23.1% of enVVeno Medical shares are held by institutional investors. 14.6% of PAVmed shares are held by company insiders. Comparatively, 16.3% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
PAVmed 14.0%的股份由機構投資者持有。相比之下,enVVeno Medical 23.1%的股份由機構投資者持有。PAVmed 14.6%的股份由公司內部人士持有。相比之下,enVVeno Medical 16.3%的股份由公司內部人士持有。強大的機構持股表明,對衝基金、大型基金管理公司和捐贈基金相信,一隻股票的長期表現將好於大盤。
Summary
摘要
enVVeno Medical beats PAVmed on 6 of the 11 factors compared between the two stocks.
EnVVeno Medical在兩隻股票比較的11個因素中有6個擊敗了PAVmed。
About PAVmed
關於PAVmed
(Get Rating)
(獲取評級)
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.
PAVmed,Inc.是一家商業階段的技術醫療器械公司,致力於醫療技術的商業化。它通過以下部門運作:醫療設備、診斷、數字健康和新興創新。其產品包括細胞採集設備、食道DNA測試、腕管釋放、植入性骨內血管接入設備和抗菌可吸收耳管。該公司成立於2014年6月26日,總部設在紐約州紐約。
About enVVeno Medical
關於enVVeno醫療公司
(Get Rating)
(獲取評級)
enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.
恩維諾醫療公司(納斯達克代碼:NVNO)是一家醫療設備公司,專注於開發創新的生物假體(基於組織的)設備,以提高靜脈疾病治療的護理標準。該公司的主導產品VenoValve是一種一流的外科植入物,正在開發用於治療嚴重的深靜脈慢性靜脈功能不全(CVI)。當腿部深靜脈內的瓣膜受損,導致返回心臟的血液不足時,就會發生深靜脈CVI。出現故障的靜脈瓣膜導致血液向後流動(迴流),並在小腿上積聚,增加腿部靜脈內的壓力(靜脈性高血壓)。在最嚴重的情況下,CVI可導致靜脈潰瘍(開放性皮膚潰瘍),成為慢性且難以治癒。靜脈瓣膜被植入股靜脈,作為替代靜脈瓣膜,旨在減少返流和靜脈高血壓,並恢復正確的定向血液迴流到心臟。據估計,美國約有240萬人受到嚴重的深靜脈CVI影響,他們沒有有效的治療選擇,VenoValve已獲得美國食品和藥物管理局指定的突破設備,目前正在SAVVE美國臨牀試驗中進行評估。
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
接受PAVmed日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對PAVmed和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧